$POET

Summary

The analyst exited their position in POET at break-even due to management issues and a significant order cancellation by Marvell. They also trimmed about 50% of their holding in TSEM to rotate elsewhere.

Reasoning

POET faced a huge order cancellation by Marvell impacting its already small revenue; the analyst lacks patience for incompetent management and regrets taking a position, leading to an exit. For TSEM, the analyst trimmed holdings due to concerns about foundry exposure and to rotate elsewhere.

Earnings next week for across sectors like semis, space, and power. Companies like $NBIS, $ASTS, and $PLUG all report. I think we’re all looking forward to hearing from $POET’s CFO too? TLDR Summary: Monday: $ASTS: scheduled June SpaceX launches (addressing prior delays) + fresh defense contracts incl. U.S. Missile Defense Agency SHIELD program + recent partnership momentum w/ AT&T, Verizon & Vodafone. The only real negative has been launch execution risk from recent BlueBird 7 setback. Fresh delays / funding concerns could pressure valuation short term. $HIMS: last quarter was huge ($2.35B rev = +59% YoY). Since then: launched Novo Nordisk branded GLP-1’s after legal settlement + heavy institutional buying. Short interest still high at ~35%. Key signals are: subscriber growth past 2.5M, GLP-1 traction without margin erosion + raise of the FY $2.7-2.9B rev guide. $CRCL: riding momentum from Q4 - rev up 77% YoY ($770M) & solid EPS beat. Since then: new institutional payment platforms launched + expanded African partnerships. Tailwinds from potential U.S. stablecoin legislation + diversification into services. Valuation is way too high rn for me to consider, especially w/ risks in crypto sentiment / margin pressure. $PLUG: Recent narrative has been mixed: services & hydrogen rev growth + DOE loan progress are the positives. But high cash burn, capex needs + seasonal Q1 weakness are the downsides. GM sustainability/expansion, backlog conversion (e.g. Canada wins), liquidity updates + explicit confirmation of the 2026 path to positive EBITDA are all crucial. Tuesday: ChipMOS: shown strong momentum recently after weak 2025 - Customer demand visibility now extends past 2026: Q1 results tracking strong MRR, improving utilization/margins + sustained AI tailwinds into the full year. $SATL: recently signed $12M sovereign defense contract + expanded defense/intel sales team. Still a small base but the AI Earth-observation thesis needs clear rev acceleration, backlog wins, Merlin constellation progress (Oct 2026 target), and cash discipline. $CAMT: don’t think there’s many updates apart from recent Visual Layer acquisition to bolster inspection capabilities? As with most AI supply chain names, you’d want: strong backlog/orders, + clear pipeline visibility. Wednesday: $NBIS: Eigen AI acquisition + hyperscaler deployments ( $MSFT / $META) have enhanced the AI-infra narrative. To justify premium neocloud valuation: Q1 rev/ARR progress, capacity-ramp updates, Eigen integration traction. Hyperscaler execution + backlog conversion would reinforce the 5x+ growth story. $TSEM: Would be looking for healthy customer mix (RF/power/SiGe) + AI comments. Fab-loading strength would confirm a durable cycle, but weakness would highlight foundry exposure. I personally trimmed ~50% of my holding over the last month to rotate elsewhere. Thursday: $POET: order cancellation by $MRVL was huge for them since rev is already tiny. So to offset that, they’d need to signal Malaysia production ramp confirmation + any new hyperscaler wins. Visible revenue inflection + backlog would validate the shift to commercialization. Personally don’t have patience for incompetent management (regret taking a position), so sold out of my position at break-even after that whole Marvell fiasco.

Return by horizon